Today Moderna faces a crisis unlike any other in its 15-year-history. Wall Street has pushed executives to slash spending, as Covid vaccine sales have slumped and no new blockbusters have emerged. The federal government, which had all but midwifed the company, has turned on it. In May, the Health and Human Services Department — led by Secretary Robert F. Kennedy Jr., who has touted falsehoods about mRNA vaccines — canceled $766 million in contracts to prepare shots for a potential bird flu pandemic. Moderna reported revenues of $142 million in the last reported quarter, representing a year-over-year change of -41.1%.
Due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, Moderna is rated Zacks Rank #3 (Hold). The previous big move we wrote about was 3 days ago when the stock dropped 3.5% on the news that the stock retreated, giving back some of the strong gains from the previous session that were fueled by reports of potential buyout or partnership discussions. This significant jump was driven by multiple reports indicating Moderna was in strategic negotiations with at least one major pharmaceutical company regarding a potential acquisition.
- The story of Moderna’s great unraveling — told here in detail, with new disclosures about the pressures the company has faced and the missteps it has made — is neither simple nor finished.
- Moderna (MRNA Quick QuoteMRNA – Free Report) is one of the stocks most watched by Zacks.com visitors lately.
- In 2024, Moderna’s revenue was $3.24 billion, a decrease of -52.75% compared to the previous year’s $6.85 billion.
- This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system.
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
The speculation came as the biotech firm had faced pressure from tapering sales of its COVID-19 vaccines. The decline represented a partial reversal of the previous session’s sharp rally as some of the initial excitement appeared to cool. For the next fiscal year, the consensus earnings estimate of $7.27 indicates a change of +25.4% from what Moderna is expected to report a year ago.
Moderna: Failure of Cytomegalovirus Vaccine Further Increases Pressure on Oncology Pipeline
- Whether a stock’s current price rightly reflects the intrinsic value of the underlying business and the company’s growth prospects is an essential determinant of its future price performance.
- Moreover, analysts forecasted the company would report a substantial quarterly loss with revenues declining by over 53% compared to the year-ago quarter.
- These returns cover a period from January 1, 1988 through October 6, 2025.
- You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer.
The story of Moderna’s great unraveling — told here in detail, with new disclosures about the pressures the company has faced and the missteps it has made — is neither simple nor finished. At the end of this year, the company will still have $6 billion in the bank, a Covid shot with more than $1 billion in sales annually, and a cancer vaccine that has tantalized oncologists and analysts alike with its potential to revive that moribund field. “They’re not going anywhere,” said Melissa Moore, Moderna’s former chief scientist of mRNA research. Mast interviewed more than two dozen former and current Moderna employees, along with analysts, rival executives, investors, and experts in mRNA and vaccines to understand how the company arrived at this treacherous moment and where it goes from here.
Investors are now focused on the company’s earnings report, due Thursday. Consensus estimates project a quarterly loss of approximately $2.15 per share on revenue of about $860 million. In the case of Moderna, the consensus sales estimate of $860.07 million for the current quarter points to a year-over-year change of -53.8%.
ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Today, I am highlighting three biotech stocks I like in the current market that are trading at under $10.00 a share. The options on these stocks are also lucrative and liquid, making them well-suited … Moderna, Inc. faces significant uncertainty ahead of Q3 earnings, with heavy reliance on COVID vaccine revenues and limited pipeline progress. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment. The beta is 2.01, so Moderna’s price volatility has been higher than the market average.
The company beat consensus EPS estimates in each of the trailing four quarters. The company topped consensus revenue estimates three times over this period. According to 15 analysts, the average rating for MRNA stock is “Hold.” The 12-month stock price target is $37.15, which is an increase of 57.68% from the latest price.
S&P 500 Gains and Losses Today: Meta Stock Drops After Earnings; Moderna Surges
This positive step was tempered by the fallout from the company’s Oct. 23 update, when it announced it was stopping the Phase 3 trial for its cytomegalovirus vaccine, mRNA-1647, after it failed to meet its primary efficacy endpoint. That news prompted several analyst actions, including a target cut to $40 by UBS and a $25 target from JPMorgan, which maintained an Underweight rating. The stock market overreacts to news, and big price drops can present good opportunties to buy high-quality stocks.
Moderna Reports Promising Response Rates For Skin Cancer Combo Therapy In Resistant Patients
Moderna is set to report earnings soon, with expectations of a 58.7% year-on-year revenue decline. The nucleic acid therapeutics market is projected to grow significantly, which may benefit Moderna’s expanding pipeline in cancer therapies, despite recent setbacks and stock volatility. Rather than focusing on anything else, we at Zacks prioritize evaluating the change in a company’s earnings projection. This is because we believe the fair value for its stock is determined by the present value of its future stream of earnings. Shares of a social media juggernaut slumped as investors balked at its rapidly accelerating spending on artificial intelligence, while reports of potential partnership or buyout talks helped a vaccine…
Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer. Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts. Having a strong externally audited track record, our proprietary stock rating tool, the Zacks Rank, offers a more conclusive picture of a stock’s price direction in the near term, since it effectively harnesses the power of earnings estimate revisions.
Moderna Stops CMV Program As Vaccine Falls Short In Preventing Infection
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.93% per year. These returns cover a period from January 1, 1988 through October 6, 2025.
Moderna (MRNA Quick QuoteMRNA – Free Report) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Moderna (MRNA) remains a Sell due to weak fundamentals, ongoing cash burn, and lack of meaningful pipeline breakthroughs or financial turnaround. Moderna and BioNTech were the main ‘saviors’ of people and economies from COVID-19. However, since the pandemic ended, their stock prices have fallen by more than 70%.
The facts discussed here and much other information on Zacks.com might help determine whether or not it’s worthwhile paying attention to the What Is Ethereum market buzz about Moderna. However, its Zacks Rank #3 does suggest that it may perform in line with the broader market in the near term. Moderna said on Tuesday its updated COVID-19 vaccine formulation elicited a strong immune response in all adults aged 65 and older, as well as in individuals aged 12 to 64 with at least one underlying… The Moderna Innovation and Technology Centre in Harwell, Oxfordshire is now fully operational and Moderna is licensed to supply British-made COVID-19 vaccines to the UK population The facility marks a… Company to discontinue development of mRNA-1647 in congenital CMV Company will continue to evaluate mRNA-1647 in ongoing Phase 2 trial in bone marrow transplant patients Company does not anticipate an… In 2024, Moderna’s revenue was $3.24 billion, a decrease of -52.75% compared to the previous year’s $6.85 billion.
Zacks Research is Reported On:
Compared to the Zacks Consensus Estimate of $127.17 million, the reported revenues represent a surprise of +11.66%. Courtney Breen, Bernstein senior analyst, joins ‘The Exchange’ to discuss the companies exempt from pharma tariffs, the country’s with existing trade deals and much more. Top stories, top movers, and trade ideas delivered to your inbox every weekday before and after the market closes.
Enterprise Valuation
Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations.
The Fast Money traders discuss why health care stocks look attractive on valuations, how underweight positioning could drive sustainability, why recent White House policy moves may be a “gift” to phar… Select to analyze similar companies using key performance metrics; select up to 4 stocks. In the last 12 months, operating cash flow was -$2.70 billion and capital expenditures -$793.00 million, giving a free cash flow of -$3.49 billion. In the last 12 months, Moderna had revenue of $3.08 billion and -$2.90 billion in losses. Moderna is down 40.2% since the beginning of the year, and at $25.13 per share, it is trading 53.1% below its 52-week high of $53.54 from November 2024. Investors who bought $1,000 worth of Moderna’s shares 5 years ago would now be looking at an investment worth $363.74.
Our analysis is essentially based on how sell-side analysts covering the stock are revising their earnings estimates to take the latest business trends into account. When earnings estimates for a company go up, the fair value for its stock goes up as well. And when a stock’s fair value is higher than its current market price, investors tend to buy the stock, resulting in its price moving upward. Because of this, empirical studies indicate a strong correlation between trends in earnings estimate revisions and short-term stock price movements. While Moderna announced it had dosed the first patient in a Phase 1/2 study for a multiple myeloma therapy, investors looked past this development.